B. Topp

Applications of Quantitative Systems Pharmacology in Model‐Informed Drug Discovery: Perspective on Impact and Opportunities

Rhys D O Jones, Jason R. Chan, M. Spilker, 2019, CPT: pharmacometrics & systems pharmacology.

Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and α-PD-1

P. Berraondo, I. Trocóniz, D. D. de Alwis, 2021, British Journal of Cancer.

Beyond the single average tumor: Understanding IO combinations using a clinical QSP model that incorporates heterogeneity in patient response

Rukmini Kumar, K. Mayawala, D. D. de Alwis, 2021, CPT: pharmacometrics & systems pharmacology.

Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab.

M. Hellmann, D. D. de Alwis, A. Snyder, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors

Zinnia P. Parra-Guillen, P. Berraondo, I. Trocóniz, 2021, Cancers.

Incorporating lesion-to-lesion heterogeneity into early oncology decision making

Rukmini Kumar, B. Topp, Timothy Qi, 2023, Frontiers in Immunology.

RECISTv1.1 progression in oncology: Shades of gray.

A. Snyder, B. Topp, J. Wolchok, 2023, Cancer cell.

Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape

Fan Wu, Brian Topp, Bianca M. Liederer, 2018, CPT: pharmacometrics & systems pharmacology.